Literature DB >> 16828603

Pathogenesis of thrombocytopenia in cyanotic congenital heart disease.

Michael C Lill1, Joseph K Perloff, John S Child.   

Abstract

Although a significant minority of patients with cyanotic congenital heart disease (CCHD) are thrombocytopenic, the pathogenesis and prevalence have not been established. This study was designed to address these 2 issues. We included 105 patients with CCHD (60 men and 45 women; aged 21 to 54 years). Systemic arterial oxygen saturations were 69% to 78%. Hematocrits were 62% to 74% with normal iron indexes. In 26 of 105 patients (25%), platelet counts were <100x10(9)/L. The diagnosis was Eisenmenger syndrome in all 26 patients with thrombocytopenia. Platelet production was determined by flow cytometric reticulated platelet counts. Megakaryocyte mass was determined indirectly by thrombopoietin levels. Disseminated intravascular coagulation was based on prothrombin time, activated partial thromboplastin time, and D-dimers. Platelet activation was determined by levels of platelet factor 4 and beta thromboglobulin. Reference ranges were derived from 20 normal acyanotic controls. A reduction in absolute reticulated platelet counts implied decreased platelet production (p<0.001). Normal thrombopoietin levels implied normal megakaryocyte mass. Normal prothrombin time, activated partial thromboplastin time, and D-dimers excluded disseminated intravascular coagulation. Normal platelet factor 4 and beta thromboglobulin indicated absent or minimal platelet activation. Twenty-five percent of the patients with CCHD were thrombocytopenic because platelet production was decreased despite normal megakaryocyte mass. We hypothesized that right-to-left shunts deliver whole megakaryocytes into the system arterial circulation, bypassing the lungs where megakaryocytic cytoplasm is fragmented into platelets, thus reducing platelet production. In conclusion, platelet counts in CCHD appear to represent a continuum beginning with low normal counts and ending with thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828603     DOI: 10.1016/j.amjcard.2006.01.083

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

1.  Infusion of mature megakaryocytes into mice yields functional platelets.

Authors:  Rudy Fuentes; Yuhuan Wang; Jessica Hirsch; Cheng Wang; Lubica Rauova; G Scott Worthen; M Anna Kowalska; Mortimer Poncz
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

2.  Threading an elephant through the eye of a needle: Where are platelets made?

Authors:  Ian Johnston; Vincent Hayes; Mortimer Poncz
Journal:  Cell Res       Date:  2017-05-09       Impact factor: 25.617

3.  Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale.

Authors:  Yuhuan Wang; Vincent Hayes; Danuta Jarocha; Xiuli Sim; Dawn C Harper; Rudy Fuentes; Spencer K Sullivan; Paul Gadue; Stella T Chou; Beverly J Torok-Storb; Michael S Marks; Deborah L French; Mortimer Poncz
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

Review 4.  Platelet Biogenesis in the Lung Circulation.

Authors:  Emma Lefrançais; Mark R Looney
Journal:  Physiology (Bethesda)       Date:  2019-11-01

5.  A triple challenge: thrombocytopenia in a 7-year-old girl with unrepaired d-transposition of the great arteries, ventricular septal defect, and pulmonary hypertension.

Authors:  Mohammed Al-Biltagi; Mohamed F Ismail; Osman O Al-Radi; Haysam Baho
Journal:  Pediatr Cardiol       Date:  2012-11-11       Impact factor: 1.655

6.  Potential contribution of erythrocyte microRNA to secondary erythrocytosis and thrombocytopenia in congenital heart disease.

Authors:  Nobuhiro Mukai; Yoshinobu Nakayama; Satoshi Murakami; Toshihito Tanahashi; Daniel I Sessler; Sachiyo Ishii; Satoru Ogawa; Natsuko Tokuhira; Toshiki Mizobe; Teiji Sawa; Yasufumi Nakajima
Journal:  Pediatr Res       Date:  2018-01-17       Impact factor: 3.756

7.  Massive epistaxis in a patient with Eisenmenger syndrome: illustrating the clot-versus-bleed conundrum.

Authors:  Alexander Liu; Harman Saman; Pawan Pusalkar
Journal:  BMJ Case Rep       Date:  2011-08-04

Review 8.  Metabolic syndrome and coronary artery disease in adults with congenital heart disease.

Authors:  Koichiro Niwa
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

9.  Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.

Authors:  Christian Opitz; Ekkehard Grünig; Stephan Rosenkranz; Ann-Sophie Kaemmerer; Matthias Gorenflo; Dörte Huscher; David Pittrow; Peter Ewert; Christine Pausch; Marion Delcroix; Hossein A Ghofrani; Marius M Hoeper; Rainer Kozlik-Feldmann; Andris Skride; Gerd Stähler; Carmine Dario Vizza; Elena Jureviciene; Dovile Jancauskaite; Lina Gumbiene; Ralf Ewert; Ingo Dähnert; Matthias Held; Michael Halank; Dirk Skowasch; Hans Klose; Heinrike Wilkens; Katrin Milger; Christian Jux; Martin Koestenberger; Laura Scelsi; Eva Brunnemer; Michael Hofbeck; Silvia Ulrich; Anton Vonk Noordegraaf; Tobias J Lange; Leonhard Bruch; Stavros Konstantinides; Martin Claussen; Judith Löffler-Ragg; Hubert Wirtz; Christian Apitz; Rhoia Neidenbach; Sebastian Freilinger; Attila Nemes
Journal:  Cardiovasc Diagn Ther       Date:  2021-12

10.  Prevalence and associated factors of renal dysfunction and proteinuria in cyanotic congenital heart disease.

Authors:  Nattaphorn Hongsawong; Prapimdaw Khamdee; Suchaya Silvilairat; Wattana Chartapisak
Journal:  Pediatr Nephrol       Date:  2017-10-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.